Clinical Trial Update: An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

Open-label, randomized study comparing intravenous pamrevlumab to standard of care in COVID-19 patients; study phases 2 and 3 have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Pamrevlumab (pamrevlumab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: COVID-19 Respiratory Infection, COVID-19 Pneumonia | Phase 2, Phase 3 | Status: COMPLETED